Is vasopressin-receptor antagonism an advancement in the treatment of heart failure?

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.10, 2004-10, pp. : 2181-2184

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vasopressin receptor antagonists in heart failure

By Thibonnier M.

Current Opinion in Pharmacology, Vol. 3, Iss. 6, 2003-12 ,pp. : 683-687

Elsevier

Access to resources Recommend Favorite

Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 3, 2006-09 ,pp. : 249-258

Bentham Science Publishers

Access to resources Recommend Favorite

Vasopressin receptor antagonists in the management of acute heart failure

By Tang WH Wilson Bhavnani Sanjeev Francis Gary S

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite

V₂ receptor antagonism with tolvaptan in heart failure

By Costello-Boerrigter Lisa C Boerrigter Guido Burnett John C

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 10, 2007-10 ,pp. : 1639-1647

Informa Healthcare

Access to resources Recommend Favorite

Vasopressin Receptor Antagonists: Therapeutic Potential in the Management of Acute and Chronic Heart Failure

By Russell S.D. DeWald T.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 1, 2003-01 ,pp. : 13-20

Adis International

Access to resources Recommend Favorite